Patents
Patents for A61K 51 - Preparations containing radioactive substances for use in therapy or testing in vivo (24,291)
02/2005
02/22/2005US6858584 For therapy of bacterial disease in a mammal; side effect reduction
02/22/2005US6858386 Using cancer marker protein to detect, classify, evaluate and prevent cell proliferative disorders
02/22/2005US6858187 Apparatus for the preparation of a radioactive aqueous solution
02/17/2005WO2005015155A2 Methods for comparing relative flux rates of two or more biological molecules in vivo through a single protocol
02/17/2005WO2005014479A2 Process for preparing radiolabeled compounds
02/17/2005WO2005014052A1 Radioimmunoconjugates for targeted alpha therapy
02/17/2005WO2005014051A1 Emulsion particles for imaging and therapy and methods of use thereof
02/17/2005WO2005013897A2 Magnetic nanoparticle compositions, and methods related thereto
02/17/2005WO2004028338A3 A method to demonstrate the efficacy of pharmacological stress agent
02/17/2005US20050037005 5c8 Antigen
02/17/2005US20050036948 Radiolabeled annexins
02/17/2005CA2536659A1 Process
02/17/2005CA2534687A1 Magnetic nanoparticle compositions, and methods related thereto
02/17/2005CA2534426A1 Emulsion particles for imaging and therapy and methods of use thereof
02/16/2005EP1506027A1 Cell delivery fluid for prevention of cell settling in delivery system
02/16/2005EP1506018A1 Drug pre-targeting by means of bi-specific antibodies and hapten constructs comprising a carrier peptide and the active agent(s)
02/16/2005EP1505973A2 Methods and compositions using immunomodulatory compounds for treatment and management of cancers and other diseases
02/16/2005EP1505955A1 Short chain polymer for enhancing the bioadhesiveness of polymers on mucosal membrane
02/16/2005CN1582166A Vitronectin receptor antagonist pharmaceuticals for use in combination therapy
02/15/2005US6855810 Ligands directed to the non-secretory component, non-stalk region of plgR and methods of use thereof
02/15/2005US6855309 For use in diagnostics and therapy
02/15/2005US6855308 Anticancer, antitumor agents
02/15/2005US6855103 Radioactive implantable devices and methods and apparatuses for their production and use
02/10/2005WO2005012493A2 Anti-cd19 antibodies
02/10/2005WO2005012489A2 Targeting endothelium for tissue-specific delivery of agents
02/10/2005WO2005011738A2 Polymeric conjugates containing phosphine - based chelating groups
02/10/2005WO2005011612A2 Alpha 4 beta 2 delta gaba-a receptors as a strategy for pms and alcoholism
02/10/2005WO2004093856A3 Combination of a cox-2 inhibitor and an alkylating-type antineoplastic agent for treatment of neoplasia
02/10/2005US20050033057 Thiazoline acid derivatives
02/10/2005US20050033048 Spiro[isobenzofuran-1,4'-piperidin]-3-ones and 3h-spiroisobenzofuran-1,4'-piperidines
02/10/2005US20050033030 Humanised antibodies and uses thereof
02/10/2005US20050033026 Immunoconjugates for the treatment of tumours
02/10/2005US20050033024 Expression vector comprising nucleotide sequences coding cytokine receptor for use as tool in identifying modulators for prevention and treatment allergic, skin and respiratory disorders
02/10/2005US20050032789 Novel compounds useful in pain management
02/10/2005US20050032676 Administering lipidated glycopeptide antibiotic and cyclodextrin, reduced tissue accumulation of the glycopeptide antibiotic, reduced nephrotoxicity and reduced histamine release
02/10/2005US20050032148 Diagnostic agents for pancreatic exocrine function
02/10/2005US20050031630 Immunogen (antibody determinant, lipid, peptide, and/or carbohydrate) derived from virus/cancer cell with mast cell membrane activator; microbiocides; wound healing agents; reduced scarring
02/10/2005CA2537899A1 Tissue-specific targeting of therapeutic and imaging agents to caveolae
02/10/2005CA2534639A1 Anti-cd19 antibodies
02/09/2005EP1503805A1 Lyophilized edible food incorporating a marker
02/09/2005EP1503804A1 Radiopharmaceutical formulations
02/09/2005EP1056860B1 High affinity humanized anti-tag-72 monoclonal antibodies
02/09/2005CN1188410C Nonsteroid IL-5 inhibitor, its preparation method and medical composition containing the same inhibitor
02/08/2005US6852842 Methods for functional kidney imaging using small dendrimer contrast agents
02/03/2005WO2005010048A2 Rg1 antibodies and uses thereof
02/03/2005WO2005009963A1 Chelants and macrocyclic metal complex radiopharmaceuticals tihereof
02/03/2005WO2005009597A2 Methods for comparing relative flux rates of two or more biological molecules in vivo through a single protocol
02/03/2005WO2005009480A2 Implants containing codrugs
02/03/2005WO2005009479A1 Radiolabeled cannabinoid-1 receptor modulators
02/03/2005WO2005009423A1 Necrosis avid tracer agent
02/03/2005WO2005009393A2 Stable radiopharmaceutical compositions and methods for preparation
02/03/2005WO2004071425A3 The combined use of cruciferous indoles and chelators for the treatment of papillomavirus-related conditions
02/03/2005WO2004006860A3 Compositions and uses thereof for identifying and targeting provasopressin-expressing cancer cells
02/03/2005WO2003064606A3 Human monoclonal antibodies to prostate specific membrane antigen (psma)
02/03/2005US20050026955 Radiolabeled piperidine derivatives; chelate compounds; complexes with technetium
02/03/2005US20050026864 Bisphosphonate conjugates and methods of making and using the same
02/03/2005US20050026839 Conformationally constrained parathyroid hormone (pth) analogs
02/03/2005US20050026820 reducing nephrotoxicity; increased therapeutic window for the glycopeptide to allow a greater amount to be administered
02/03/2005US20050026211 Compositions and methods relating to lung specific genes
02/03/2005US20050026178 Allosteric probes and methods
02/03/2005US20050025815 Protonated/acidified nucleic acids are effective as bactericidal and/or bacteriostatic agents
02/03/2005US20050025702 radiotherapeutic or chemotherapeutic agents comprising metalloenzyme inhibitors and chelation compounds capable of conjugating to cytotoxic radioisotopes; anticarcinogenic agents
02/03/2005DE10331439B3 Magnetische Nanopartikel mit verbesserten Magneteigenschaften Magnetic nanoparticles with improved magnetic properties
02/03/2005CA2783275A1 Stable radiopharmaceutical compositions and methods for their preparation
02/03/2005CA2532394A1 Rg1 antibodies and uses thereof
02/03/2005CA2530087A1 Radiolabeled cannabinoid-1 receptor modulators
02/02/2005EP1501554A2 Benzothienyl analogue of somatostatine, selective for certain somatostatin receptors
02/02/2005EP1501551A1 Vitamin-targeted imaging agents
02/02/2005EP1401507A4 Stabilization of radionuclide-containing compositions
02/02/2005EP1131343A4 Hydrophilic somatostatin analogs
02/02/2005CN1575337A Mammalian receptor proteins; related reagents and methods
02/02/2005CN1575302A Human tissue factor antibodies
02/01/2005CA2385369C Radiation source for endovascular radiation treatment in form of a wire
01/2005
01/27/2005WO2004098650A3 Prosthetic groups attached to stannyl polymer in the synthesis of radiopharmaceuticals
01/27/2005WO2003076565A3 Methods of using 46828, a human acyl-coa synthetase
01/27/2005US20050020931 Management of gastro-intestinal disorders
01/27/2005US20050019845 Immunoconjugates of antibodies and cytotoxic agents (ricin, taxol); for treament of cancer and metastasis; tomography
01/27/2005US20050019257 Radioactive magnetic fluids for treatment or diagnosis of cancer, process for preparing them and use thereof
01/27/2005US20050019254 Combination of intercalating organometallic complexes and tumor seeking biomolecules for dna cleavage and radiotherapy
01/27/2005US20050019253 Using concentration of pancreatic exocrine enzymes visualized by 13C-labeled oligosaccharide or polysaccharide to detect pancreatitis and/or pancreatic cancer
01/27/2005US20050019252 Diagnostic agents for pancreatic exocrine function
01/27/2005US20050019251 Administering isotope labeled water to tissue; measurement; calibration
01/26/2005EP1499730A1 Immunoconjugates for the treatment of tumours
01/26/2005EP1499614A1 Adenosine a3 receptor modulators
01/26/2005EP1499584A2 Tumor imaging compounds
01/26/2005EP1499353A2 Antibodies that specifically bind to tl5
01/26/2005EP1499351A2 Antibodies that specifically bind to tr2
01/26/2005EP1307239A4 Radiopharmaceutical for diagnostic imaging containing a technetium-99m nitride heterocomplex
01/26/2005EP1233752B1 Radiation sensitive liposomes
01/26/2005EP0975373B1 Radionuclide associated with nucleotide polyphosphate as tumor imaging agents
01/26/2005CN1571680A PACAP compositions and methods for tumor imaging and therapy
01/25/2005US6846476 Treatment of B-cell associated diseases
01/25/2005CA2123224C Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of t-lymphocytes
01/20/2005WO2005006356A1 Magnetic nanoparticles having improved magnetic properties
01/20/2005WO2005004809A2 Multivalent carriers of bi-specific antibodies
01/20/2005WO2004096292A3 Use of a tetrapeptide acsdkp analogue resistant to the angiotensin i conversion enzyme, for measuring glomerular filtration rate in a human or an animal and kit containing same
01/20/2005WO2004050698A3 Peptide conjugate useful for cell nucleus molecular imaging and tumor therapy
01/20/2005WO2003057155A3 Monoclonal antibody imaging and therapy of tumors that express met and bind hepatocyte growth factor
01/20/2005US20050014939 E.g., N-[4-(2-Pyrrolidinylethoxy)phenyl]-4-oxo-4,5,6,7-tetrahydro-1H-indole-3-carboxamide; treating diseases associated with pathogenic agonism, inverse agonism or antagonism of the GABAA receptor such as anxiety, depression, a sleep disorder, or cognitive impairment
01/20/2005US20050014693 Transmission and, or amplification of signals; oral or enteric administering, dissolving, absorption of peptide yy; obesity therapy